Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution

Bulletin Express08-07

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration has approved the drug-registration application for Levosalbutamol Hydrochloride Nebuliser Solution, developed and manufactured by its subsidiary Fosun Pharma (Xuzhou) Co., Ltd.

The newly approved product is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children aged six and above with reversible obstructive airway disease. It is classified as a Class 3 chemical drug and will be marketed under approval number Guo Yao Zhun Zi H202654902. The formulation is a 3 ml:0.63 mg nebuliser solution (calculated as C13H21NO3).

Fosun Pharma has invested approximately RMB5.66 million to bring the therapy to market as of June 2026. According to IQVIA CHPA data, China’s (excluding Hong Kong, Macau and Taiwan) market for Levosalbutamol Hydrochloride Nebuliser Solution reached around RMB73.00 million in sales during 2025, highlighting a measurable but modest revenue pool.

Management expects the approval to broaden the group’s respiratory portfolio; however, future sales will depend on market demand, competitive dynamics and distribution efficiencies, which may introduce variability in commercial outcomes.

The board affirms the accuracy and completeness of the disclosed information and reminds investors of potential market-performance uncertainties inherent in new pharmaceutical launches.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191123792?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191123792","market":"hk","top_or_hot":-1,"title":"Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration has approved the drug-registration application for Levosalbutamol Hydrochloride Nebuliser Solution, developed and manufactured by its subsidiary Fosun Pharma (Xuzhou) Co., Ltd.</p>\n<p>The newly approved product is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children aged six and above with reversible obstructive airway disease. It is classified as a Class 3 chemical drug and will be marketed under approval number Guo Yao Zhun Zi H202654902. The formulation is a 3 ml:0.63 mg nebuliser solution (calculated as C13H21NO3).</p>\n<p>Fosun Pharma has invested approximately RMB5.66 million to bring the therapy to market as of June 2026. According to IQVIA CHPA data, China’s (excluding Hong Kong, Macau and Taiwan) market for Levosalbutamol Hydrochloride Nebuliser Solution reached around RMB73.00 million in sales during 2025, highlighting a measurable but modest revenue pool.</p>\n<p>Management expects the approval to broaden the group’s respiratory portfolio; however, future sales will depend on market demand, competitive dynamics and distribution efficiencies, which may introduce variability in commercial outcomes.</p>\n<p>The board affirms the accuracy and completeness of the disclosed information and reminds investors of potential market-performance uncertainties inherent in new pharmaceutical launches.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-07 20:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration has approved the drug-registration application for Levosalbutamol Hydrochloride Nebuliser Solution, developed and manufactured by its subsidiary Fosun Pharma (Xuzhou) Co., Ltd.</p>\n<p>The newly approved product is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children aged six and above with reversible obstructive airway disease. It is classified as a Class 3 chemical drug and will be marketed under approval number Guo Yao Zhun Zi H202654902. The formulation is a 3 ml:0.63 mg nebuliser solution (calculated as C13H21NO3).</p>\n<p>Fosun Pharma has invested approximately RMB5.66 million to bring the therapy to market as of June 2026. According to IQVIA CHPA data, China’s (excluding Hong Kong, Macau and Taiwan) market for Levosalbutamol Hydrochloride Nebuliser Solution reached around RMB73.00 million in sales during 2025, highlighting a measurable but modest revenue pool.</p>\n<p>Management expects the approval to broaden the group’s respiratory portfolio; however, future sales will depend on market demand, competitive dynamics and distribution efficiencies, which may introduce variability in commercial outcomes.</p>\n<p>The board affirms the accuracy and completeness of the disclosed information and reminds investors of potential market-performance uncertainties inherent in new pharmaceutical launches.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1191123792","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191123792","pubTimestamp":1786105573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration has approved the drug-registration application for Levosalbutamol...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药获得NMPA批准左沙丁胺醇雾化器溶液","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration has approved the drug-registration application for Levosalbutamol Hydrochloride Nebuliser Solution, developed and manufactured by its subsidiary Fosun Pharma (Xuzhou) Co., Ltd.\nThe newly approved product is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children aged six and above with reversible obstructive airway disease. It is classified as a Class 3 chemical drug and will be marketed under approval number Guo Yao Zhun Zi H202654902. The formulation is a 3 ml:0.63 mg nebuliser solution (calculated as C13H21NO3).\nFosun Pharma has invested approximately RMB5.66 million to bring the therapy to market as of June 2026. According to IQVIA CHPA data, China’s (excluding Hong Kong, Macau and Taiwan) market for Levosalbutamol Hydrochloride Nebuliser Solution reached around RMB73.00 million in sales during 2025, highlighting a measurable but modest revenue pool.\nManagement expects the approval to broaden the group’s respiratory portfolio; however, future sales will depend on market demand, competitive dynamics and distribution efficiencies, which may introduce variability in commercial outcomes.\nThe board affirms the accuracy and completeness of the disclosed information and reminds investors of potential market-performance uncertainties inherent in new pharmaceutical launches.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191123792","isCrawlerRequest":true}